379 related articles for article (PubMed ID: 16151584)
1. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Lemez P; Urbánek V
Neoplasma; 2005; 52(5):398-401. PubMed ID: 16151584
[TBL] [Abstract][Full Text] [Related]
2. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
Lemez P; Maresová J
Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
[TBL] [Abstract][Full Text] [Related]
4. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
5. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
6. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia.
Gillis S; Dann EJ; Rund D
Am J Hematol; 1996 Jan; 51(1):26-31. PubMed ID: 8571934
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
8. Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults.
Ohno R; Yokomaku S; Okumura M; Nagai T; Kitaori K; Ito T; Takeo T; Sugiura I; Yano K; Ito Y
Int J Hematol; 1991 Dec; 54(6):487-93. PubMed ID: 1793832
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology.
N Z Med J; 1991 Oct; 104(922):438-40. PubMed ID: 1923103
[TBL] [Abstract][Full Text] [Related]
10. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
[TBL] [Abstract][Full Text] [Related]
11. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
Damon LE; Rugo HS; Ries CA; Linker CA
Leukemia; 1994 Apr; 8(4):535-41. PubMed ID: 8152248
[TBL] [Abstract][Full Text] [Related]
12. [Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Chubachi A; Kuriya S; Narigasawa Y; Meguro K; Endo K; Takami H; Sato S; Sasaki H; Shiga T; Maruyama Y
Gan To Kagaku Ryoho; 1995 Dec; 22(14):2101-6. PubMed ID: 8607622
[TBL] [Abstract][Full Text] [Related]
13. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
14. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy in canine acute megakaryoblastic leukemia: a case report and review of the literature.
Willmann M; Müllauer L; Schwendenwein I; Wolfesberger B; Kleiter M; Pagitz M; Hadzijusufovic E; Shibly S; Reifinger M; Thalhammer JG; Valent P
In Vivo; 2009; 23(6):911-8. PubMed ID: 20023232
[TBL] [Abstract][Full Text] [Related]
16. [Low-dose oral etoposide and subcutaneous injection of low-dose cytosine arabinoside (Et-A non i.v.) with or without minimum anthracycline for refractory acute non-lymphoblastic leukemia].
Tsukaguchi M; Furukawa Y; Kitani T
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1603-7. PubMed ID: 9725056
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872.
Béhar C; Suciu S; Benoit Y; Robert A; Vilmer E; Boutard P; Bertrand Y; Lutz P; Ferster A; Tokaji E; Manel AM; Solbu G; Otten J
Med Pediatr Oncol; 1996 Mar; 26(3):173-9. PubMed ID: 8544799
[TBL] [Abstract][Full Text] [Related]
18. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
[TBL] [Abstract][Full Text] [Related]
19. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
Waga K; Furusawa S; Nagashima S; Saito K; Shishido H
Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
